Powder: -20°C for 3 years | In solvent: -80°C for 1 year
KDM5-C70 是 KDM5-C49 的乙酯衍生物,是一种有效的细胞渗透性泛 KDM5 组蛋白去甲基化酶抑制剂。它在骨髓瘤细胞中具有抗增殖作用,可诱导全基因组 H3K4me3 水平升高。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 253 | 现货 | ||
2 mg | ¥ 362 | 现货 | ||
5 mg | ¥ 589 | 现货 | ||
10 mg | ¥ 856 | 现货 | ||
25 mg | ¥ 1,450 | 现货 | ||
50 mg | ¥ 2,350 | 现货 | ||
100 mg | ¥ 3,970 | 现货 | ||
200 mg | ¥ 5,880 | 现货 | ||
500 mg | ¥ 9,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 729 | 现货 |
产品描述 | KDM5-C70 is an ethyl ester derivative of KDM5-C49. KDM5-C70 is an effective, cell-permeable, and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, inducing a genome-wide elevation of H3K4me3 levels. |
体外活性 | KDM5-C70 (50 μM; 7 days; MM.1S myeloma cells) treatment reduces the level of phosphorylation of retinoblastoma protein (Rb) while leaving the total level of phosphorylated Rb (pRb) unchanged, indicating impairment of cell cycle progression. KDM5-C70 (1 nM-10 μM; 7 days; MM.1S myeloma cells) treatment displays antiproliferative effects after 7 days of treatment at elevated concentrations (estimated 50% reduction of viability/proliferation for KDM5-C70 at ~20 μM). Chromatin immunoprecipitation followed by next-generation sequencing displays an enhanced H3K4me3 level around transcription start sites with KDM5-C70 but little change with GSK467A at 50 μM inhibitor concentrations [1]. |
分子量 | 336.43 |
分子式 | C17H28N4O3 |
CAS No. | 1596348-32-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 250 mg/mL (743.10 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9724 mL | 14.8619 mL | 29.7239 mL | 74.3097 mL |
5 mM | 0.5945 mL | 2.9724 mL | 5.9448 mL | 14.8619 mL | |
10 mM | 0.2972 mL | 1.4862 mL | 2.9724 mL | 7.431 mL | |
20 mM | 0.1486 mL | 0.7431 mL | 1.4862 mL | 3.7155 mL | |
50 mM | 0.0594 mL | 0.2972 mL | 0.5945 mL | 1.4862 mL | |
100 mM | 0.0297 mL | 0.1486 mL | 0.2972 mL | 0.7431 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
KDM5-C70 1596348-32-1 Chromatin/Epigenetic Histone Demethylase KDM5-C49 JARID1 retinoblastoma inhibit KDM5 C70 KDM-5-C70 phosphorylation KDM5C70 KDM5 Inhibitor H3K4me3 antiproliferative inhibitor